Bluebird’s $175M loan; Spyre reveals second private placement

Plus, news about Fen­nec, As­traZeneca, Bio­mX and Pfiz­er:

Blue­bird bio gets more mon­ey: The gene ther­a­py mak­er inked a five-year, $175 mil­lion loan fa­cil­i­ty with Her­cules Cap­i­tal, start­ing with $75 mil­lion in the first batch. Blue­bird is com­mer­cial­iz­ing its three new­ly ap­proved gene ther­a­pies. — Kyle LaHu­cik

Spyre Ther­a­peu­tics rais­es an­oth­er $180M: Three months af­ter an­nounc­ing a $180 mil­lion pri­vate place­ment, the Boston-area IBD drug­mak­er is back again for the same amount. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.